RAD 502 / Radiopharm Theranostics, Lantheus - LARVOL DELTA

Radiopharm Receives Strategic Investment for up to A$18 million (GlobeNewswire) - "Radiopharm Theranostics Limited...has entered into strategic agreements with Lantheus Holdings...and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement. The net proceeds of Lantheus’ investment will be used by the Company for drug manufacturing, clinical trials and general working capital....Under a separate transfer and development agreement, Radiopharm has assigned and sub-licensed two of its preclinical assets to Lantheus for A$3.0 million (US$2.0 million). Assets covered under the agreement are a TROP2 targeting nanobody and a LRRC15 targeting mAb."

Financing • Licensing / partnership • Solid Tumor

FDA Grants Orphan Drug Designation to DUNP19 for Osteosarcoma (OncLive) - "The FDA has granted an orphan drug designation (ODD) to DUNP19 for the treatment of osteosarcoma, according to an announcement from Radiopharm Theranostics. DUNP19, a dual-action, LRRC15-targeted monoclonal antibody, is a first-in-class therapy with dual-action tumor targeting designed to find, internalize, and destroy both cancer cells and cells in the tumor microenvironment."

Orphan drug • Oncology • Osteosarcoma • Sarcoma • Solid Tumor